Company: BIAF
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024163
Chunk: 12

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 12
---
 results of operations, and cash flow.

Advertising
Expense

The
Company expenses all advertising costs as incurred. Advertising expense was $171,822 and $131,125 for the six months ended June 30, 2025
and 2024, respectively, and $143,616 and $119,205 for the three months ended June 30, 2025 and 2024, respectively.

Loss
Per Share

Basic
loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of the Company’s
Common Stock outstanding during the period. Diluted loss per share is computed by dividing net loss attributable to common stockholders
by the sum of the weighted-average number of shares of Common Stock outstanding during the period and the weighted-average number of
dilutive Common Stock equivalents outstanding during the period, using the treasury stock method. Dilutive Common Stock equivalents are
comprised of in-the-money stock options, convertible notes payable, unvested restricted stock, and warrants based on the average stock
price for each period using the treasury stock method.

    10

The
following potentially dilutive securities have been excluded from the computations of weighted-average shares of Common Stock outstanding
as of June 30, 2025 and 2024, as they would be anti-dilutive:

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES

    2025  
    2024 

    As of June 30, 

    2025  
    2024 
  
    Shares underlying options outstanding 
     304,125  
     337,810 
  
    Shares underlying warrants outstanding 
     28,193,118  
     8,838,669 
  
    Shares underlying unvested restricted stock 
     282,940  
     246,044 
  
    Anti-dilutive securities 
     28,780,183  
     9,422,523 

Revenue
Recognition

To
determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts
with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance
obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in
the contract, and (5) recognize revenue